Literature DB >> 28596159

In Vivo Relationship Between Hypoxia and Angiogenesis in Human Glioblastoma: A Multimodal Imaging Study.

Keven Ferreira da Ponte1,2, David Hassanein Berro1,2, Solène Collet1, Jean-Marc Constans1,3, Evelyne Emery2,4, Samuel Valable1, Jean-Sébastien Guillamo5,6,7.   

Abstract

Glioblastoma multiforme (GBM) is the most common and aggressive primary brain tumor. This aggressiveness is in part attributed to the closely interrelated phenomena tumor hypoxia and angiogenesis, although few in vivo data exist in human brain tumors. This work aimed to study hypoxia and angiogenesis, in vivo and in situ, in patients admitted with GBM using multimodal imaging.
Methods: Twenty-three GBM patients were assessed by 18F-fluoromisonidazole (18F-FMISO) PET and conventional and perfusion MRI before surgery. The level and location of hypoxia (18F-FMISO uptake, evaluated by tumor-to-blood [T/B] ratio), vascularization (cerebral blood volume [CBV]), and vascular permeability (contrast enhancement after gadolinium injection) were analyzed. The spatial relationship between tumor hypoxia and angiogenesis was assessed by an overlap analysis of the volume of 18F-FMISO uptake and the volumes of the high CBV regions and the contrast-enhancement regions.
Results: A significant correlation was found between hypoxia and hypervascularization, especially for their maximum values (volume of maximal tumor hypoxia vs. relative CBV: r = 0.61, P = 0.002) and their volumes (hypoxia vs. hypervascularization: r = 0.91, P < 0.001). A large proportion of the high CBVs collocated with hypoxia (81.3%) and with contrast enhancement (46.5%).
Conclusion: These results support the hypothesis of a tight association between hypoxia and angiogenesis. Our results suggest that there is insufficient tumor oxygenation in human GBM, despite increased tumor vascularization.
© 2017 by the Society of Nuclear Medicine and Molecular Imaging.

Entities:  

Keywords:  18F-FMISO PET; MRI; angiogenesis; glioblastoma; hypoxia

Mesh:

Substances:

Year:  2017        PMID: 28596159     DOI: 10.2967/jnumed.116.188557

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  15 in total

1.  Simultaneous pH-sensitive and oxygen-sensitive MRI of human gliomas at 3 T using multi-echo amine proton chemical exchange saturation transfer spin-and-gradient echo echo-planar imaging (CEST-SAGE-EPI).

Authors:  Robert J Harris; Jingwen Yao; Ararat Chakhoyan; Catalina Raymond; Kevin Leu; Linda M Liau; Phioanh L Nghiemphu; Albert Lai; Noriko Salamon; Whitney B Pope; Timothy F Cloughesy; Benjamin M Ellingson
Journal:  Magn Reson Med       Date:  2018-04-06       Impact factor: 4.668

Review 2.  Molecular and functional imaging insights into the role of hypoxia in cancer aggression.

Authors:  Samata Kakkad; Balaji Krishnamachary; Desmond Jacob; Jesus Pacheco-Torres; Eibhlin Goggins; Santosh Kumar Bharti; Marie-France Penet; Zaver M Bhujwalla
Journal:  Cancer Metastasis Rev       Date:  2019-06       Impact factor: 9.264

3.  Association between Tumor Acidity and Hypervascularity in Human Gliomas Using pH-Weighted Amine Chemical Exchange Saturation Transfer Echo-Planar Imaging and Dynamic Susceptibility Contrast Perfusion MRI at 3T.

Authors:  Y-L Wang; J Yao; A Chakhoyan; C Raymond; N Salamon; L M Liau; P L Nghiemphu; A Lai; W B Pope; N Nguyen; M Ji; T F Cloughesy; B M Ellingson
Journal:  AJNR Am J Neuroradiol       Date:  2019-05-16       Impact factor: 3.825

Review 4.  Cellular Conversations in Glioblastoma Progression, Diagnosis and Treatment.

Authors:  Ali Karimi Sisakht; Mohammad Malekan; Farbod Ghobadinezhad; Seyedeh Negar Mousavi Firouzabadi; Ameneh Jafari; Seyed Mohammad Ali Mirazimi; Banafshe Abadi; Rana Shafabakhsh; Hamed Mirzaei
Journal:  Cell Mol Neurobiol       Date:  2022-04-11       Impact factor: 5.046

Review 5.  Nutrient metabolism and cancer in the in vivo context: a metabolic game of give and take.

Authors:  Patricia Altea-Manzano; Alejandro M Cuadros; Lindsay A Broadfield; Sarah-Maria Fendt
Journal:  EMBO Rep       Date:  2020-09-23       Impact factor: 8.807

6.  Mechanism-Specific Pharmacodynamics of a Novel Complex-I Inhibitor Quantified by Imaging Reversal of Consumptive Hypoxia with [18F]FAZA PET In Vivo.

Authors:  Seth T Gammon; Federica Pisaneschi; Madhavi L Bandi; Melinda G Smith; Yuting Sun; Yi Rao; Florian Muller; Franklin Wong; John De Groot; Jeffrey Ackroyd; Osama Mawlawi; Michael A Davies; Y N Vashisht Gopal; M Emilia Di Francesco; Joseph R Marszalek; Mark Dewhirst; David Piwnica-Worms
Journal:  Cells       Date:  2019-11-21       Impact factor: 6.600

7.  Vascular dysfunction promotes regional hypoxia after bevacizumab therapy in recurrent glioblastoma patients.

Authors:  Elizabeth R Gerstner; Kyrre E Emblem; Yi-Fen Yen; Jorg Dietrich; Justin T Jordan; Ciprian Catana; Kevin Lou Wenchin; Jacob M Hooker; Dan G Duda; Bruce R Rosen; Jayashree Kalpathy-Cramer; Rakesh K Jain; Tracy T Batchelor
Journal:  Neurooncol Adv       Date:  2020-11-17

Review 8.  Tumor Hypoxia Regulates Immune Escape/Invasion: Influence on Angiogenesis and Potential Impact of Hypoxic Biomarkers on Cancer Therapies.

Authors:  Raefa Abou Khouzam; Klaudia Brodaczewska; Aleksandra Filipiak; Nagwa Ahmed Zeinelabdin; Stephanie Buart; Cezary Szczylik; Claudine Kieda; Salem Chouaib
Journal:  Front Immunol       Date:  2021-01-20       Impact factor: 7.561

9.  Metastatic renal cell carcinoma cells growing in 3D on poly‑D‑lysine or laminin present a stem‑like phenotype and drug resistance.

Authors:  Klaudia K Brodaczewska; Zofia F Bielecka; Kamila Maliszewska-Olejniczak; Cezary Szczylik; Camillo Porta; Ewa Bartnik; Anna M Czarnecka
Journal:  Oncol Rep       Date:  2019-09-18       Impact factor: 3.906

10.  A Dual Receptor Targeting- and BBB Penetrating- Peptide Functionalized Polyethyleneimine Nanocomplex for Secretory Endostatin Gene Delivery to Malignant Glioma.

Authors:  Lu Lu; Hongyuan Chen; Longkun Wang; Lin Zhao; Yanna Cheng; Aijun Wang; Fengshan Wang; Xinke Zhang
Journal:  Int J Nanomedicine       Date:  2020-11-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.